KTTA, KTTAW · CIK 0001841330 · operating
Pasithea Therapeutics is a clinical-stage biotechnology company focused on developing treatments for central nervous system disorders, RASopathies, and select cancers. The company's lead program, PAS-004, is a next-generation MEK inhibitor designed to address neurofibromatosis type 1 and other RASopathy-driven conditions, as well as MAPK pathway-driven tumors including BRAF-mutant cancers. PAS-004 is also being evaluated for ETS2-driven inflammatory diseases such as inflammatory bowel disease and primary sclerosing cholangitis. The company is also advancing PAS-003 for amyotrophic lateral sclerosis and has development plans for PAS-001, targeting schizophrenia.
As a pre-revenue clinical-stage company, Pasithea does not currently generate revenue from product sales. The company operates with a minimal internal workforce of four full-time employees, reflecting the typical structure of early-stage biotechnology firms that rely on contract research organizations and external partners for development activities.
Incorporated in Delaware in 2020, Pasithea is headquartered in Miami Beach, Florida and trades on the Nasdaq exchange. The company operates primarily in the United States market.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.42 | $-0.42 | +0.0% | |
| 2023 | $-0.42 | $-0.42 | +20.8% | |
| 2022 | $-0.53 | $-0.55 | -152.4% | |
| 2021 | — | $-0.21 | — |